Research programme: anti-infectives - Crescent Biopharma
Alternative Names: Carbohydrate mimics for bacterial infections - Crescent Biopharma; GMI-1051Latest Information Update: 17 Jun 2025
At a glance
- Originator GlycoMimetics
- Developer Crescent Biopharma
- Class Small molecules
- Mechanism of Action Lectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 16 Jun 2025 GlycoMimetics has merged with Crescent Biopharma to form Crescent Biopharma
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA
- 08 Sep 2014 Pharmacodynamics data from preclinical studies in pseudomonal infections released by GlycoMimetics